

## RoyaltySource® Royalty Rates Database

Thank you for requesting further information about our RoyaltySource® Royalty Rates database of intellectual property sale and licensing transactions. Shown below is typical information relating to a technology license, formatted as you would receive it.

### **Technology**

**Licensee: NONINVASIVE MEDICAL TECHNOLOGIES LLC**

**Licensor: LIFE SIGNS DETECTION SYSTEMS, INC.**

**Royalty Rate, % (low range):** 5  
**Royalty Rate, % (high range):** 5  
**Upfront Fee:** \$300,000

#### **Licensed Property:**

This Agreement is entered into this 6th day of March, 2006.

The Canadian Licensor hereby grants to the Licensee and/or its successors and assigns a perpetual license to use and further develop the Licensee's Technology and acknowledges the Licensee's full ownership of any derivative, related or spin-off technologies which directly utilize the Licensee's RF technology for vital signs monitoring (collectively the "Derivative Technologies").

The Licensor represents that it is the owner of certain technology which will provide heartbeat waveform and respiration waveform through two layers of normal wear clothing/

The Licensee was granted the use of technology that will provide heartbeat and respiration waveform through two layers of normal wear clothing.

The Licensee has also entered into a contract with the U.S. Military whereby it is developing what is known as the Marco Polo project E-Tag system in connection with its desire to attempt to utilize the vital signs monitoring technology.

Term: Perpetual

#### **Compensation Items:**

Upfront Fee: Initial Payment of Three Hundred Thousand (\$300,000) Dollars.

**Royalty:** Life Signs Detection Systems ("LSDS") will receive a royalty of 5% of the actually paid gross sales of any derivative products that incorporate LSDS's RF technology for vital signs monitoring which are based on LSDS's hardware, software, technology, trade secrets and intellectual property conveyed. The royalty will not exceed 50% of the actual net profits on annual commercial sales. LSDS will also receive a royalty of 5% of the actually paid annual gross sales of the E/Tag device in connection with sales to the military/government, not to exceed 50% of the actual net annual profits.

**Source:** Form SB-2 NONINVASIVE MEDICAL TECHNOLOGIES INC Exhibit 10.11, 02/13/2007  
[http://www.sec.gov/Archives/edgar/data/1389538/000114420407006747/v064881\\_ex10-11.htm](http://www.sec.gov/Archives/edgar/data/1389538/000114420407006747/v064881_ex10-11.htm)

*The source of information provided in this report has been gathered from public financial records, news releases, and other articles and references. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided.*